Treatment of Fabry disease: Outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

被引：0
|
作者：
Vedder, A. C.
Linthorst, G. E.
Houge, G.
Groener, J. E. M.
Ormel, E. E.
Bouma, B. J.
Aerts, J. M. F. G.
Hirth, A.
Hollak, C. E. M.
机构：
[1] AMC, Dept Intern Med Endocr Metab, Amsterdam, Netherlands
[2] Haukeland Hosp, N-5021 Bergen, Norway
[3] AMC, Dept Biochem Med, Amsterdam, Netherlands
[4] AMC, Dept Cardiol, Amsterdam, Netherlands
[5] Haukeland Hosp, Dept Heart Dis, N-5021 Bergen, Norway
来源：
JOURNAL OF INHERITED METABOLIC DISEASE | 2007年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [41] Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
    Beck, Michael
    Hughes, Derralynn
    Kampmann, Christoph
    Larroque, Sylvain
    Mehta, Atul
    Pintos-Morell, Guillem
    Ramaswami, Uma
    West, Michael
    Wijatyk, Anna
    Giugliani, Roberto
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2015, 3 : 21 - 27
  • [42] Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa
    Wendt, S
    Whybra, C
    Kampmann, C
    Teichmann, E
    Beck, M
    JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 (05) : 787 - 788
  • [43] Prospective Results of Switching Enzyme Replacement Therapy from Agalsidase beta to Agalsidase alfa in the Canadian Fabry Disease Initiative Study
    West, Michael
    Bichet, Daniel
    Casey, Robin
    Clarke, Joe
    Sirrs, Sandra
    Flowerdew, Gordon
    LeMoine, Kaye
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S64 - S65
  • [44] Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial
    Ramaswami, Uma
    Bichet, Daniel G.
    Clarke, Lorne A.
    Dostalova, Gabriela
    Fainboim, Alejandro
    Fellgiebel, Andreas
    Forcelini, Cassiano M.
    Haack, Kristina An
    Hopkin, Robert J.
    Mauer, Michael
    Najafian, Behzad
    Scott, C. Ronald
    Shankar, Suma P.
    Thurberg, Beth L.
    Tondel, Camilla
    Tylki-Szyrnanska, Anna
    Benichou, Bernard
    Wijburg, Frits A.
    MOLECULAR GENETICS AND METABOLISM, 2019, 127 (01) : 86 - 94
  • [45] Early initiation of agalsidase alfa treatment improves clinical outcomes in male patients with classical Fabry disease: A Fabry Outcome Survey (FOS) analysis
    Morell, Guillem Pintos
    Kampmann, Christoph
    Botha, Jaco
    Anagnostopoulou, Christina
    West, Michael L.
    Ramaswami, Uma
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 105 - 105
  • [46] Agalsidase alfa and agalsidase beta in Fabry disease - our experience of reported infusion reactions over a 9-year period
    Milligan, A.
    Hughes, D.
    Brooks, L.
    Goodwin, S.
    Jennings, A.
    Ajoku, U.
    Pringle, S.
    Richfield, L.
    Mehta, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 : S60 - S60
  • [47] Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
    van Kuilenburg, Andre B. P.
    Hollak, Carla E. M.
    Travella, Ana
    Jacobs, Melisa
    Gentilini, Lucas D.
    Leen, Rene
    van der Vlugt, Karen M. M. Ghauharali
    Stet, Femke S. Beers
    Goorden, Susan M. I.
    van der Veen, Sanne
    Criscuolo, Marcelo
    Papouchado, Mariana
    DRUGS IN R&D, 2023, 23 (02) : 141 - 153
  • [48] Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease
    Tasci, Elif Senocak
    Bicik, Zerrin
    IRANIAN JOURNAL OF KIDNEY DISEASES, 2015, 9 (05) : 406 - 408
  • [49] Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
    André B. P. van Kuilenburg
    Carla E. M. Hollak
    Ana Travella
    Melisa Jacobs
    Lucas D. Gentilini
    René Leen
    Karen M. M. Ghauharali-van der Vlugt
    Femke S. Beers Stet
    Susan M. I. Goorden
    Sanne van der Veen
    Marcelo Criscuolo
    Mariana Papouchado
    Drugs in R&D, 2023, 23 : 141 - 153
  • [50] EFFECT AND TOLERABILITY OF AGALSIDASE ALFA WERE ASSESSED IN PATIENTS WITH FABRY DISEASE WHO WERE TREATMENT-NAIVE (NAIVE) OR PREVIOUSLY TREATED WITH AGALSIDASE BETA (SWITCH PATIENTS)
    Goker-Alpan, Ozlem
    Ibrahim, Jennifer
    Nedd, Khan
    Shankar, Suma
    Lein, Howard
    Barshop, Bruce
    Boyd, Ellen
    Holida, Myrl
    Hillman, Richard
    Ibrahim, Jennifer
    Mardach, Rebecca
    Wienreb, Neil
    Rever, Barbara
    Forte, Richard
    Desai, Alpana
    Wijatyk, Anna
    Chang, Peter
    Martin, Rick
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 316 - 316
12345